| Literature DB >> 29150462 |
Kazuichi Maruyama1,2, Tohru Inaba3, Sunao Sugita4, Ryo Ichinohasama5, Kenji Nagata2, Shigeru Kinoshita2, Manabu Mochizuki6, Toru Nakazawa1.
Abstract
PURPOSE: To determine the clinical relevance of vitreous biomarkers in patients with uveitis.Entities:
Keywords: cd4/cd8 ratio; flowcytometry analysis; uveitis; vitreous sample
Mesh:
Substances:
Year: 2017 PMID: 29150462 PMCID: PMC5701993 DOI: 10.1136/bmjopen-2016-014549
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Patients details
| Disease (cases) | Number (case/eye) | Age (mean±SD) | Gender (M:F) |
| D-S | |||
| Skin biopsy: 16 | |||
| Lung biopsy: 15 | 46/61 | 67.0±8.6 | 6:40 |
| Clinical manifestation: 15 | |||
| S-S | 45/60 | 67.6±6.5 | 5:40 |
| Tumour/PIOL | |||
| DLBCL: 23 | |||
| T-LGL leukaemia: 2 | 27/34 | 67.4±14.5 | 13:14 |
| ATL: 1 | |||
| NK: 1 | |||
| Viral infection | |||
| VZV: 4 | |||
| HSV-1: 2 | |||
| HSV-2: 2 | 18/20 | 55.4±16.8* | 11:7 |
| CMV: 7 | |||
| HTLV-1: 3 | |||
| Non-sarcoidosis | |||
| Endophthalmitis: 10 | |||
| Behçet: 2 | 16/16 | 66.8±9.5 | 9:7 |
| Toxocara: 2 | |||
| Toxoplasma: 2 | |||
| Unknown | 39/43 | 61.6±2.9 | 14:25 |
| 191/234 | *V: D-S, V: S-S (p<0.05) | 47:118 |
All patients underwent vitreous analysis.
ATL, adult T-cell lymphoma; CMV, cytomegalovirus; DLBCL, diffuse large B-cell lymphoma; D-S, definitive sarcoidosis; HTLV-1, human T-cell leukemia virus; HSV, herpes simplex virus; NK, natural killer cell tumour; S-S, suspected sarcoidosis; PIOL, primary intraocular lymphoma; T-LGL, T-cell large granular lymphocyte leukemia; VZV, varicella zoster virus.
Figure 1Ranks: Kruskal-Wallis test of the (A) CD4/CD8 ratio, (B) CD4, (C) CD8 and (D) CD19 in the vitreous samples from several types of uveitis. Significant differences in each group are indicated by the asterisks **** or *** p<0.001, **p<0.01, *p<0.05. D, definitive sarcoidosis; S, suspected sarcoidosis.
CD4/CD8 lymphocyte ratios in vitreous samples
| n | Mean | SD | Difference in average value | Effect size: d | p Value | |
| D-sarcoidosis | 61 | 38.12 | 124.90 | 16.99 | 0.22 | >0.9999 |
| S-sarcoidosis | 60 | 21.13 | 29.94 | |||
| D-sarcoidosis | 61 | 38.12 | 124.90 | 34.86 | 0.54 | <0.0001 |
| Non-sarcoidosis | 16 | 3.26 | 3.84 | |||
| D-sarcoidosis | 61 | 38.12 | 124.90 | 36.64 | 0.58 | <0.0001 |
| Viral infection | 20 | 1.48 | 1.07 | |||
| D-sarcoidosis | 61 | 38.12 | 124.90 | 36.25 | 0.57 | <0.0001 |
| Tumour | 34 | 1.87 | 3.37 | |||
| D-sarcoidosis | 61 | 38.12 | 124.90 | 5.85 | 0.04 | 0.0014 |
| Unknown | 43 | 32.27 | 146.80 | |||
| S-sarcoidosis | 60 | 21.13 | 29.94 | 17.87 | 1.06 | <0.0001 |
| Non-sarcoidosis | 16 | 3.26 | 3.84 | |||
| S-sarcoidosis | 60 | 21.13 | 29.94 | 19.65 | 1.27 | <0.0001 |
| Viral infection | 20 | 1.48 | 1.07 | |||
| S-sarcoidosis | 60 | 21.13 | 29.94 | 19.26 | 1.16 | <0.0001 |
| Tumour | 34 | 1.87 | 3.37 | |||
| S-sarcoidosis | 60 | 21.13 | 29.94 | 11.14 | 0.13 | 0.0086 |
| Unknown | 43 | 32.27 | 146.80 | |||
| Non-sarcoidosis | 16 | 3.26 | 3.84 | 1.78 | 0.73 | >0.9999 |
| Viral infection | 20 | 1.48 | 1.07 | |||
| Non-sarcoidosis | 16 | 3.26 | 3.84 | 1.39 | 0.39 | >0.9999 |
| Tumour | 34 | 1.87 | 3.37 | |||
| Non-sarcoidosis | 16 | 3.26 | 3.84 | 29.01 | 0.39 | 0.4573 |
| Unknown | 43 | 32.27 | 146.80 | |||
| Viral infection | 20 | 1.48 | 1.07 | 0.39 | 0.18 | >0.9999 |
| Tumour | 34 | 1.87 | 3.37 | |||
| Viral infection | 20 | 1.48 | 1.07 | 30.79 | 0.42 | 0.0063 |
| Unknown | 43 | 32.27 | 146.80 | |||
| Tumour | 34 | 1.87 | 3.37 | 30.40 | 0.40 | 0.0002 |
| Unknown | 43 | 32.27 | 146.80 |
CD4+ lymphocyte ratios in vitreous samples
| n | Mean | SD | Difference in average value | Effect size: d | p Value | |
| D-sarcoidosis | 61 | 87.27 | 8.28 | 0.44 | 0.06 | >0.9999 |
| S-sarcoidosis | 60 | 87.71 | 7.37 | |||
| D-sarcoidosis | 61 | 87.27 | 8.28 | 35.74 | 2.08 | <0.0001 |
| Non-sarcoidosis | 16 | 51.53 | 26.15 | |||
| D-sarcoidosis | 61 | 87.27 | 8.28 | 39.07 | 2.85 | <0.0001 |
| Viral infection | 20 | 48.20 | 19.16 | |||
| D-sarcoidosis | 61 | 87.27 | 8.28 | 47.68 | 3.15 | <0.0001 |
| Tumour | 34 | 39.59 | 22.03 | |||
| D-sarcoidosis | 61 | 87.27 | 8.28 | 14.07 | 0.96 | 0.0122 |
| Unknown | 43 | 73.20 | 21.02 | |||
| S-sarcoidosis | 60 | 87.71 | 7.37 | 36.18 | 2.16 | <0.0001 |
| Non-sarcoidosis | 16 | 51.53 | 26.15 | |||
| S-sarcoidosis | 60 | 87.71 | 7.37 | 39.51 | 2.98 | <0.0001 |
| Viral infection | 20 | 48.20 | 19.16 | |||
| S-sarcoidosis | 60 | 87.71 | 7.37 | 48.12 | 3.27 | <0.0001 |
| Tumour | 34 | 39.59 | 22.03 | |||
| S-sarcoidosis | 60 | 87.71 | 7.37 | 14.51 | 1.02 | 0.0083 |
| Unknown | 43 | 73.20 | 21.02 | |||
| Non-sarcoidosis | 16 | 51.53 | 26.15 | 3.33 | 0.15 | >0.9999 |
| Viral infection | 20 | 48.20 | 19.16 | |||
| Non-sarcoidosis | 16 | 51.53 | 26.15 | 11.94 | 0.50 | >0.9999 |
| Tumour | 34 | 39.59 | 22.03 | |||
| Non-sarcoidosis | 16 | 51.53 | 26.15 | 21.67 | 0.92 | 0.111 |
| Unknown | 43 | 73.20 | 21.02 | |||
| Viral infection | 20 | 48.20 | 19.16 | 8.61 | 0.42 | >0.9999 |
| Tumour | 34 | 39.59 | 22.03 | |||
| Viral infection | 20 | 48.20 | 19.16 | 25.00 | 1.24 | 0.0056 |
| Unknown | 43 | 73.20 | 21.02 | |||
| Tumour | 34 | 39.59 | 22.03 | 33.61 | 1.56 | <0.0001 |
| Unknown | 43 | 73.20 | 21.02 |
CD8 lymphocyte ratios in vitreous samples
| n | Mean | SD | Difference in average value | Effect size: d | p Value | |
| D-sarcoidosis | 61 | 7.81 | 6.50 | 1.25 | 0.19 | >0.9999 |
| S-sarcoidosis | 60 | 9.06 | 6.83 | |||
| D-sarcoidosis | 61 | 7.81 | 6.50 | 21.03 | 1.67 | 0.0008 |
| Non-sarcoidosis | 16 | 28.84 | 18.69 | |||
| D-sarcoidosis | 61 | 7.81 | 6.50 | 35.37 | 2.89 | <0.0001 |
| Viral infection | 20 | 43.18 | 17.97 | |||
| D-sarcoidosis | 61 | 7.81 | 6.50 | 32.47 | 2.56 | <0.0001 |
| Tumour | 34 | 40.28 | 18.87 | |||
| D-sarcoidosis | 61 | 7.81 | 6.50 | 14.84 | 1.12 | 0.0006 |
| Unknown | 43 | 22.65 | 20.01 | |||
| S-sarcoidosis | 60 | 9.06 | 6.83 | 19.78 | 1.55 | 0.0039 |
| Non-sarcoidosis | 16 | 28.84 | 18.69 | |||
| S-sarcoidosis | 60 | 9.06 | 6.83 | 34.12 | 2.75 | <0.0001 |
| Viral infection | 20 | 43.18 | 17.97 | |||
| S-sarcoidosis | 60 | 9.06 | 6.83 | 31.22 | 2.43 | <0.0001 |
| Tumour | 34 | 40.28 | 18.87 | |||
| S-sarcoidosis | 60 | 9.06 | 6.83 | 13.59 | 1.01 | 0.0055 |
| Unknown | 43 | 22.65 | 20.01 | |||
| Non-sarcoidosis | 16 | 28.84 | 18.69 | 14.34 | 0.78 | 0.8786 |
| Viral infection | 20 | 43.18 | 17.97 | |||
| Non-sarcoidosis | 16 | 28.84 | 18.69 | 11.44 | 0.61 | >0.9999 |
| Tumour | 34 | 40.28 | 18.87 | |||
| Non-sarcoidosis | 16 | 28.84 | 18.69 | 6.19 | 0.32 | >0.9999 |
| Unknown | 43 | 22.65 | 20.01 | |||
| Viral infection | 20 | 43.18 | 17.97 | 2.90 | 0.16 | >0.9999 |
| Tumour | 34 | 40.28 | 18.87 | |||
| Viral infection | 20 | 43.18 | 17.97 | 20.53 | 1.08 | 0.0068 |
| Unknown | 43 | 22.65 | 20.01 | |||
| Tumour | 34 | 40.28 | 18.87 | 17.63 | 0.91 | 0.0045 |
| Unknown | 43 | 22.65 | 20.01 |
CD19 lymphocyte ratios in vitreous samples
| n | Mean | SD | Difference in average value | Effect size: d | p Value | |
| D-sarcoidosis | 61 | 0.42 | 0.82 | 0.16 | 0.26 | >0.9999 |
| S-sarcoidosis | 60 | 0.27 | 0.37 | |||
| D-sarcoidosis | 61 | 0.42 | 0.82 | 0.28 | 0.31 | >0.9999 |
| Non-sarcoidosis | 16 | 0.70 | 0.95 | |||
| D-sarcoidosis | 61 | 0.42 | 0.82 | 1.42 | 0.63 | 0.1123 |
| Viral infection | 20 | 1.84 | 3.69 | |||
| D-sarcoidosis | 61 | 0.42 | 0.82 | 29.06 | 1.89 | <0.0001 |
| Tumour | 34 | 29.48 | 29.92 | |||
| D-sarcoidosis | 61 | 0.42 | 0.82 | 0.54 | 0.46 | 0.6018 |
| Unknown | 43 | 0.96 | 1.53 | |||
| S-sarcoidosis | 60 | 0.27 | 0.37 | 0.43 | 0.65 | >0.9999 |
| Non-sarcoidosis | 16 | 0.70 | 0.95 | |||
| S-sarcoidosis | 60 | 0.27 | 0.37 | 1.57 | 0.77 | 0.0717 |
| Viral infection | 20 | 1.84 | 3.69 | |||
| S-sarcoidosis | 60 | 0.27 | 0.37 | 29.21 | 1.93 | <0.0001 |
| Tumour | 34 | 29.48 | 29.92 | |||
| S-sarcoidosis | 60 | 0.27 | 0.37 | 0.69 | 0.73 | 0.3762 |
| Unknown | 43 | 0.96 | 1.53 | |||
| Non-sarcoidosis | 16 | 0.70 | 0.95 | 1.14 | 0.49 | >0.9999 |
| Viral infection | 20 | 1.84 | 3.69 | |||
| Non-sarcoidosis | 16 | 0.70 | 0.95 | 28.78 | 1.86 | 0.0017 |
| Tumour | 34 | 29.48 | 29.92 | |||
| Non-sarcoidosis | 16 | 0.70 | 0.95 | 0.26 | 0.21 | >0.9999 |
| Unknown | 43 | 0.96 | 1.53 | |||
| Viral infection | 20 | 1.84 | 3.69 | 27.64 | 1.64 | 0.0113 |
| Tumour | 34 | 29.48 | 29.92 | |||
| Viral infection | 20 | 1.84 | 3.69 | 0.88 | 0.34 | >0.9999 |
| Unknown | 43 | 0.96 | 1.53 | |||
| Tumour | 34 | 29.48 | 29.92 | 28.52 | 1.81 | <0.0001 |
| Unknown | 43 | 0.96 | 1.53 |
Figure 2Performance of the (A) CD4/CD8 ratios, (B) CD8+ and (C) CD19+ in the vitreous samples for the purpose of discriminating sarcoidosis and other uveitis groups in (A) receiver operator curve space; (B) performance of the CD8+ population in vitreous samples for the purpose of discriminating between the viral infection group and the other uveitis groups in the receiver operator curve space; (C) performance of CD19+ population in the vitreous samples for the purpose of discriminating between the tumour group and other uveitis groups in the receiver operator curve space. Comparisons of the diagnostic performance of the vitreal CD4/CD8 ratio, CD8+ population and CD19+ population were performed by plotting their performance results in the receiver operator curve space.
Figure 3Quantitative analysis of the preoperative and postoperative VA. Significant differences were observed (****p<0.001). VA, visual acuity.
Figure 4Flow chart for the diagnosis and categorisation of uveitis based on the vitreous samples examined by flow cytometry analysis, PCR analysis and cytokine detection.